The management of DVT in Behçet’s disease primarily emphasizes the use of immunosuppressants, although the role of anticoagulants remains debated.[4] According to EULAR guidelines, acute DVT in Behçet’s disease should be treated with glucocorticoids and immunosuppressants such as azathioprine, cyclophosphamide, or cyclosporine A. In refractory cases, monoclonal anti-TNF antibodies may be an option. This evidence concerns the gene TNF and Behcet disease.